Please select the therapeutic area you would like to see more about.
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Bamlanivimab and Etesevimab together is authorized for use under an Emergency Use Authorization for the treatment of mild to moderate COVID-19 illness in adults and pediatric patients 12 years and older, who weigh at least 40 kg, who are at high risk for progressing to severe COVID-19 illness and/or hospitalization. Bamlanivimab and Etesevimab together is an investigational drug that has not been approved by the FDA for any use. It is not yet known if bamlanivimab and etesevimab together is safe and effective for the treatment of COVID-19. This use is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use, unless the authorization is terminated or revoked sooner.
If you have immediate questions regarding COVID-19, or to report an Adverse Event or Product Complaint, please call us.